Seven Biotechs To Watch In The Hepatitis B Space - Data Intelligence

These biotech startups could change how we treat hepatitis B

Here we take a look at seven biotechs with clinical drug candidates on a quest to win regulatory approval to treat HBV. The post Seven biotechs to watch in the hepatitis B space appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full an…

Seven Biotechs To Watch In The Hepatitis B Space - Data Intelligence

Newsletter Signup – Under Article / In Page “*” indicates required fields Hepatitis B is a serious liver infection that is caused by the hepatitis B virus (HBV). Around 254 million people live with hepatitis B, and 6000 people are newly infected with viral hepatitis each day, according to the World Health Organization (WHO). However, many people remain undiagnosed in several countries, and the number of people who receive treatments remains low.…